Core Insights - SCYNEXIS, Inc. has initiated a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial for its intravenous formulation of SCY-247, an antifungal therapy aimed at treating invasive candidiasis and preventing invasive fungal diseases, with results expected in 2026 [1][2] Group 1: Company Developments - The first participants have been dosed in the Phase 1 trial of SCY-247, which has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, indicating its potential significance in treating severe fungal infections [2][3] - SCY-247's oral formulation has shown positive results in previous SAD/MAD data, demonstrating excellent pharmacokinetic and pharmacodynamic properties, achieving target exposures at lower doses than first-generation antifungals [2] - The company is exploring non-dilutive funding opportunities to support the SCY-247 program, highlighting its commitment to addressing health security threats posed by antifungal resistance [2] Group 2: Product Information - SCY-247 is part of SCYNEXIS's proprietary antifungal platform "fungerps," which includes Ibrexafungerp, already approved for treating vulvovaginal candidiasis [4] - The second-generation fungerp SCY-247 is currently in clinical development stages, with additional antifungal assets from this class in pre-clinical and discovery phases [4]

Core Insights - SCYNEXIS, Inc. announced a $22 million payment from GlaxoSmithKline (GSK) as part of resolving a disagreement regarding the Phase 3 MARIO study on invasive candidiasis [1][6] - The company will not receive additional milestone payments from GSK related to the MARIO study and will begin wind-down activities [1][6] - GSK remains committed to collaborating with SCYNEXIS on the commercialization of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) [2][6] Financial Implications - The $22 million payment, along with existing cash and the removal of future MARIO expenditures, extends SCYNEXIS's cash runway to over two years [6] - An additional payment of $2.3 million will be received by SCYNEXIS for the wind-down activities associated with the MARIO study [1] Product Development - SCYNEXIS is progressing the transfer of the BREXAFEMME New Drug Application (NDA) to GSK, expected to be completed by the end of 2025 [2] - GSK plans to initiate regulatory interactions with the U.S. FDA in 2026 to discuss the relaunch of BREXAFEMME for VVC and rVVC [2] - The company continues to develop SCY-247, a second-generation antifungal aimed at treating and preventing invasive fungal infections [3][4]